Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 12/2010

01-12-2010 | Breast Oncology

The Clinical Outcome of Chemotherapy-Induced Amenorrhea in Premenopausal Young Patients with Breast Cancer with Long-Term Follow-up

Authors: Minkyu Jung, Hyun Joon Shin, Sun Young Rha, Hei Cheul Jeung, Soojung Hong, Yong Wha Moon, Hyo Song Kim, Kyung Jin Oh, Woo Ick Yang, Jae Kyung Roh, Hyun Cheol Chung

Published in: Annals of Surgical Oncology | Issue 12/2010

Login to get access

Abstract

Background

We investigated the factors that predict chemotherapy-induced amenorrhea (CIA) and the prognostic significance of CIA after long-term follow-up.

Methods

We reviewed data from 241 premenopausal patients with breast cancer who underwent adjuvant CMF or FAC chemotherapy after breast cancer surgery between January 1995 and December 2000.

Results

The median follow-up duration was 109.8 (range, 16.6–193.1) months. The age of CIA patients was older than non-CIA patients (median, 44 (range, 28–53) years and 36 (range, 25–49) years, respectively; P < 0.001). The addition of tamoxifen to the chemotherapy increased the incidence of CIA from 48% to 63.6% (P = 0.015). The 10-year disease-free survival (DFS) rate was higher in the CIA group compared with the non-CIA group in hormonal receptor-positive patients (78.4% vs. 67%, respectively; P = 0.022), and the 10-year overall survival (OS) rate also was higher in the CIA group compared with the non-CIA group (90.8% vs. 79.7%, respectively; P = 0.041).

Conclusions

The most important predictors of CIA are age and the addition of tamoxifen to the chemotherapy. CIA is likely to have an influence on DFS and OS in premenopausal patients with breast cancer with a positive hormone receptor, and it might be used as a surrogate marker for effective chemotherapy in these young Asian patients.
Literature
1.
Kamangar F, Dores G, Anderson W. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol. 2006;24:2137.CrossRefPubMed
2.
Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). 2005 Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365:1687–717.CrossRef
3.
Walshe JM, Denduluri N, Swain SM. Amenorrhea in premenopausal women after adjuvant chemotherapy for breast cancer. J Clin Oncol. 2006;24:5769–79.CrossRefPubMed
4.
Hickey M, Peate M, Saunders CM, Friedlander M. Breast cancer in young women and its impact on reproductive function. Hum Reprod Update. 2009;15:323–39.CrossRefPubMed
5.
Parulekar WR, Day AG, Ottaway JA, et al. Incidence and prognostic impact of amenorrhea during adjuvant therapy in high-risk premenopausal breast cancer: analysis of a National Cancer Institute of Canada Clinical Trials Group Study–NCIC CTG MA.5. J Clin Oncol. 2005;23:6002–8.CrossRefPubMed
6.
Jeong J. Korean Breast Cancer Society. Nationwide Korean breast cancer data of 2004 using breast cancer registration program. J Breast Cancer. 2006;9:151–61.CrossRef
7.
Reis LAG, Melbert D, Krapcho M, et al. SEER cancer statistics review, 1975–2004. Bethesda, MD: National Cancer Institute; 2007.
8.
Han W, Ko S, Jeong J, Kim SI, Kim SW, Son BH, Ahn SH. Poor outcome of hormone receptor-positive breast cancer at very young age is due to tamoxifen resistance: nationwide survival data in Korea––a report from the Korean Breast Cancer Society. J Clin Oncol. 2007;25:2360–8.CrossRefPubMed
9.
Lee TH, Paik NS, Kim YK. Carcinoma of the breast in women 35 years of age or less. Cancer Res Treat. 1992;24:834–9.
10.
Leining MG, Gelber S, Rosenberg R, Przypyszny M, Winer EP, Partridge AH. Menopausal-type symptoms in young breast cancer survivors. Ann Oncol. 2006;17:1777–82.CrossRefPubMed
11.
Bines J, Oleske DM, Cobleigh MA. Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer. J Clin Oncol. 1996;14:1718–29.PubMed
12.
Fornier MN, Modi S, Panageas KS, Norton L, Hudis C. Incidence of chemotherapy-induced, long-term amenorrhea in patients with breast carcinoma age 40 years and younger after adjuvant anthracycline and taxane. Cancer. 2005;104:1575–9.CrossRefPubMed
13.
Swain SM, Land SR, Ritter MW, et al. Amenorrhea in premenopausal women on the doxorubicin-and-cyclophosphamide-followed-by-docetaxel arm of NSABP B-30 trial. Breast Cancer Res Treat. 2009;113:315–20.CrossRefPubMed
14.
Tham Y, Sexton K, Weiss H, Elledge R, Friedman LC, Kramer R. The rates of chemotherapy-induced amenorrhea in patients treated with adjuvant doxorubicin and cyclophosphamide followed by a taxane. Am J Clin Oncol. 2007;30:126–32.CrossRefPubMed
15.
Vanhuyse M, Fournier C, Bonneterre J. Chemotherapy-induced amenorrhea: influence on disease-free survival and overall survival in receptor-positive premenopausal early breast cancer patients. Ann Oncol. 2005;16:1283–8.CrossRefPubMed
16.
Myers SE, Schilsky RL. Prospects for fertility after cancer chemotherapy. Semin Oncol. 1992;19:597–604.PubMed
17.
Di Cosimo S, Alimonti A, Ferretti G, et al. Incidence of chemotherapy-induced amenorrhea depending on the timing of treatment by menstrual cycle phase in women with early breast cancer. Ann Oncol. 2004;15:1065–71.CrossRefPubMed
18.
Colleoni M, Gelber S, Goldhirsch A, et al. Tamoxifen after adjuvant chemotherapy for premenopausal women with lymph node-positive breast cancer: International Breast Cancer Study Group Trial 13–93. J Clin Oncol. 2006;24:1332–41.CrossRefPubMed
19.
Rose D, Davis T. Effects of adjuvant chemohormonal therapy on the ovarian and adrenal function of breast cancer patients. Cancer Res. 1980;40:4043–7.PubMed
20.
Jordan VC, Fritz NF, Tormey DC. Endocrine effects of adjuvant chemotherapy and long-term tamoxifen administration on node-positive patients with breast cancer. Cancer Res. 1987;47:624–30.PubMed
21.
Brincker H, Rose C, Rank F, et al. Evidence of a castration-mediated effect of adjuvant cytotoxic chemotherapy in premenopausal breast cancer. J Clin Oncol. 1987;5:1771–8.PubMed
22.
Goldhirsch A, Gelber RD, Castiglione M. The magnitude of endocrine effects of adjuvant chemotherapy for premenopausal breast cancer patients. The International Breast Cancer Study Group. Ann Oncol. 1990;1:183–8.PubMed
23.
Powis G, Reece P, Ahmann D, Ingle J. Effect of body weight on the pharmacokinetics of cyclophosphamide in breast cancer patients. Cancer Chemother Pharmacol. 1987;20:219–22.CrossRefPubMed
24.
Borde F, Chapelle-Marcillac I, Fumoleau P. Role of chemo-induced amenorrhea in premenopausal, node-positive, operable breast cancer patients: 9-year follow-up results of French Adjuvant Study Group (FASG) database. Breast Cancer Res Treat. 2003;82:30.
25.
de la Rochefordiere A, Asselain B, Campana F, et al. Age as prognostic factor in premenopausal breast carcinoma. Lancet. 1993;341:1039–43.CrossRef
26.
Parton M, Smith IE. Controversies in the management of patients with breast cancer: adjuvant endocrine therapy in premenopausal women. J Clin Oncol. 2008;26:745–52.CrossRefPubMed
27.
Cuzick J, Ambroisine L, Davidson N, Jakesz R, Kaufmann M, Regan M, Sainsbury R. Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: a meta-analysis of individual patient data from randomised adjuvant trials. Lancet. 2007;369:1711–23.CrossRefPubMed
28.
Francis P, Fleming G, Nasi ML, Pagani O, Perez E, Walley B. Tailored treatment investigations for premenopausal women with endocrine responsive (ER+ and/or PGR+) breast cancer: The SOFT, TEXT, and PERCHE trials. Breast. 2003;12(Suppl 1):S44.CrossRef
Metadata
Title
The Clinical Outcome of Chemotherapy-Induced Amenorrhea in Premenopausal Young Patients with Breast Cancer with Long-Term Follow-up
Authors
Minkyu Jung
Hyun Joon Shin
Sun Young Rha
Hei Cheul Jeung
Soojung Hong
Yong Wha Moon
Hyo Song Kim
Kyung Jin Oh
Woo Ick Yang
Jae Kyung Roh
Hyun Cheol Chung
Publication date
01-12-2010
Publisher
Springer-Verlag
Published in
Annals of Surgical Oncology / Issue 12/2010
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-010-1172-3

Other articles of this Issue 12/2010

Annals of Surgical Oncology 12/2010 Go to the issue

Melanomas

The Impact on Morbidity and Length of Stay of Early Versus Delayed Complete Lymphadenectomy in Melanoma: Results of the Multicenter Selective Lymphadenectomy Trial (I)

Colorectal Cancer

Reaching the Colorectal Liver Masses

Gynecologic Oncology

Para-aortic Lymphadenectomy in the Management of Preoperative Grade 1 Endometrial Cancer Confined to the Uterine Corpus

Melanomas

The Prognostic Significance of Nonsentinel Lymph Node Metastasis in Melanoma

Head and Neck Oncology

Recurrent Pleomorphic Adenoma: Results of Surgical Treatment

Colorectal Cancer

Robotic-Assisted versus Laparoscopic Surgery for Low Rectal Cancer: Case-Matched Analysis of Short-Term Outcomes